Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.

Current oncology reports - 23 Sept 2020

Bunevicius Adomas, Miller Julie, Parsons Michael

Abstract excerpt

PURPOSE OF REVIEW: Isocitrate dehydrogenase (IDH) mutation status has important prognostic implications in glioma patients, with IDH wild-type (IDH-WT) gliomas being associated with worse prognosis and shorter survival when compared with IDH mutant (IDH-mut) gliomas. Optimization of quality of life is a priority in the management of glioma patients. The goal of this systematic review was to identify studies that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cognition
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Patient Reported Outcome Measures

Share to Quality of Life

Source

Identifiers

PMID: 32965568
DOI: 10.1007/s11912-020-00978-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.PMID 32965568Read ↗

Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas.Semantic proximity Read ↗

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Semantic proximity Read ↗

Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.Semantic proximity Read ↗

Treatment and outcomes of IDH1-mutant gliomas in elderly patients.Semantic proximity Read ↗

Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.Semantic proximity Read ↗

MGMT promoter gene methylation and neurological scale improvement in glioma: a cohort studySemantic proximity Read ↗

Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.Semantic proximity Read ↗

Molecular determinants of neurocognitive deficits in glioma: based on 2021 WHO classificationSemantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.Semantic proximity Read ↗

Cognitive functioning in a cohort of high-grade glioma patients.Semantic proximity Read ↗

IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.